Parse BiosciencesBiotech leader QIAGEN NV announced the acquisition of Parse Biosciences for US$225M upfront, plus up to US$55M in milestone payments, expected to close by the end of 2025.
ADVERTISEMENT
Biotech leader QIAGEN NV announced the acquisition of Parse Biosciences for US$225M upfront, plus up to US$55M in milestone payments, expected to close by the end of 2025.